Source: Visuals from The Women s Clinic Group Limited website
March 2, 2021
Chinese biotech startup MediLink Therapeutics has raised 350 million yuan ($54.2 million) in a Series A round, while Chinese buyout firm Lunar Capital has agreed to purchase a 64.85% stake in a women’s health and in vitro fertilisation (IVF) business in Hong Kong.
Biotech startup MediLink closes $54m Series A round
MediLink Therapeutics, a Chinese biotech startup that develops innovative drugs, announced on Monday the completion of a Series A round at 350 million yuan ($54.2 million).
The Series A round consists of two tranches of transactions, including a Series A1 round led by China’s Apricot Capital, which invests in early- and growth-stage startups in the healthcare industry. Its Series A2 part was co-led by Qiming Venture Partners and Shanghai-based equity investment firm Loyal Valley Innovation Capital, with participation from Apricot.